NEW YORK (TheStreet) -- Cell Therapeutics
(CTIC) shares are climbing, up 16% to $2.94 on Thursday, after having coverage initiated with a "buy" rating by analysts at Ladenburg
The firm set a price target of $6 on the shares, suggesting a 124% increase from the stock's opening price today.
TheStreet profiled the company and its experimental Jak-2 inhibitor for myelofibrosis, pacritinib, back in January.
Must Read: Warren Buffett's 25 Favorite Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts